Tamtam Try Tamtam free
Siemens Healthineers logo

Siemens Healthineers account plan

Diagnostics image-guided cancer therapy

At a glance

Siemens Healthineers is a Munich-based medtech group in imaging, cancer care and diagnostics with €23,375 million FY2025 revenue and about 74,000 staff.

Siemens Healthineers develops, manufactures and sells imaging systems, radiotherapy and cancer-care equipment, image-guided therapy systems and in-vitro diagnostics to hospitals, laboratories, clinics, universities and research institutes. It is directly represented in more than 70 countries and sells in more than 180, with main production and development sites in Germany, the United States, India, China, Great Britain, the Republic of Korea and Slovakia. In FY2025 (year to 30 September 2025) revenue was €23,375 million, adjusted EBIT €3,855 million (margin 16.5%) and net income €2,168 million, with about 74,000 employees. The parent is registered in Munich and Siemens AG is the majority shareholder; on November 12, 2025 Siemens AG announced its intention to deconsolidate the group, preferably by a direct spin-off of 30% of the shares.

Business units

Strategic priorities

Elevating Health Globally strategy
The FY2026-FY2030 strategy replaces New Ambition and is built on Patient Twinning, Precision Therapy and Healthcare AI, with a clinical focus on neurodegenerative disease, cardiovascular disease, stroke and cancer.
Mid-term growth targets 2027-2030
Group comparable sales growth of 5-7% a year with double-digit adjusted EPS growth; 6-9% comparable growth in Imaging and Precision Therapy, Precision Therapy margins up about 100 basis points a year, and Diagnostics growing into the mid-single digits with mid-teens margins.
Value Partnerships with health systems
The group counts more than 200 Value Partnerships and an order book worth six billion euros; new US partnerships with Cleveland Clinic and Vanderbilt Health in Q3 FY2026 amount to several hundred million euros of equipment orders.
Diagnostics transformation and separation
Cost reductions from the transformation program lifted the FY2025 Diagnostics margin to 7.7%, and the unit is to move towards its own independent structure; separation costs would be treated as a portfolio measure.
Growth countries
The business in newly industrialized countries already generates sales above three billion euros with double-digit growth, according to the CEO.
Deconsolidation from Siemens AG
Preparations for the deconsolidation are well advanced, earliest in April next year, with recurring separation costs of about €50 million and refinancing of Siemens Group loans and talks on shared services and IT on track.

Latest results

In Q3 FY2026 (April-June 2026) revenue was €5,764 million, up 2.8% comparable against a strong prior-year quarter, and equipment book-to-bill reached 1.27. Adjusted EBIT rose to €1,101 million (margin 19.1% vs 16.8%), lifted by refunds of US IEEPA tariffs; before refunds the group margin was 15.4%. Net income was €676 million (+21.7%) and free cash flow €1,023 million. China revenue fell 10.3% comparable to €576 million. For FY2026 the group cut its comparable revenue growth outlook to 3.5%-4.0% because of Diagnostics and raised adjusted basic EPS guidance to €2.35-€2.45.

Investments and deals

Molecular imaging acquisition
Acquired Advanced Accelerator Applications Molecular Imaging (control from December 2, 2024), extending the PETNET radiopharmaceutical network from the US into Europe; a new radiopharmacy in the UK is the first step in Europe.
Manufacturing sites
A superconducting-magnet plant in Oxford, a crystal-growing factory for semiconductor production in Forchheim and a customer experience center in Charlotte.
R&D
R&D expenses were €1,958 million in FY2025 (R&D intensity 8%), with more than 13,000 R&D employees and the SHIFT innovation platform with centers in Erlangen, Shanghai and Bengaluru.
Diagnostics portfolio renewal
Capex on Atellica development and renewal of blood gas and urinalysis; Atellica Forte launched at ADLM with 24 assays, and a brain-health biomarker menu is being built.
Tariff mitigation
A €400 million tariff impact is to be mitigated by 2028, back-end loaded.

Challenges and risks

Diagnostics decline in China
Diagnostics market volume in China is down by about 40% versus two years ago on volume-based procurement and price controls; China is now about 10% of group revenue.
Tariffs and trade
Higher tariffs hit margins in all segments in FY2025, and in September 2025 the US launched a Section 232 investigation into medical technology product categories.
Competition
Named competitors include GE HealthCare, Philips and United Imaging Healthcare in Imaging and Roche Diagnostics, Abbott Laboratories and Danaher in Diagnostics, alongside growing Chinese competitors, IT companies and AI start-ups.
Cybersecurity
The annual report names a high threat level in healthcare, ransomware against providers and NIS2 regulation among top risks.
Supply-chain inflation and financing
Inflation in memory chips, tungsten and logistics roughly offsets tariff mitigation in FY2027, and most Siemens Group loans carry change-of-control provisions ahead of the deconsolidation.

What leadership says

“We showed great order momentum. Our synergetic core was robust on both top and bottom lines.”

Bernd Montag, Chief Executive Officer · Q3 FY2026 earnings release, July 31, 2026

“We are the partner of choice for the design of entire healthcare systems.”

Bernd Montag, Chief Executive Officer · Speech at the Annual Shareholders' Meeting, February 5, 2026

“The next step is now for Diagnostics to consistently pursue own strategy – and derived from that, its own independent structure.”

Bernd Montag, Chief Executive Officer · Speech at the Annual Shareholders' Meeting, February 5, 2026

“the final step in a journey that started with our legal separation 10 years ago”

Bernd Montag, Chief Executive Officer · Q3 FY2026 earnings call, July 31, 2026, on the Siemens AG deconsolidation

Where a supplier can help

Separation services and IT
The deconsolidation from Siemens AG requires refinancing and new arrangements for shared services and IT, an opening for IT, finance and shared-service providers.
Diagnostics cost and carve-out support
The Diagnostics transformation and move to an independent structure create demand for restructuring, operations and separation expertise.
Supply chain and tariff mitigation
The €400 million tariff mitigation plan and inflation in memory chips, tungsten and logistics point to sourcing, localization and logistics suppliers.
Healthcare AI and cybersecurity
Healthcare AI is one leg of the strategy and cybersecurity is a named top risk, relevant to AI, software and security vendors.
Manufacturing capacity ramp
Site readiness lagged DryCool MR output and the new Varian platform will at first deliver less than market demand, pointing to installation, automation and production-capacity partners.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Siemens Healthineers?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Siemens Healthineers

What does Siemens Healthineers do?

It develops, manufactures and sells imaging systems, radiotherapy and image-guided therapy equipment and in-vitro diagnostics to hospitals, laboratories and clinics in more than 180 countries.

What was Siemens Healthineers' revenue?

FY2025 revenue (year to 30 September 2025) was €23,375 million, up 5.9% comparable, with adjusted EBIT of €3,855 million.

How many employees does Siemens Healthineers have?

About 74,000 employees at September 30, 2025.

What is Siemens Healthineers' strategy?

Elevating Health Globally (FY2026-FY2030) combines Patient Twinning, Precision Therapy and Healthcare AI, targeting 5-7% comparable growth a year with double-digit adjusted EPS growth.

Who leads Siemens Healthineers?

Dr. Bernd Montag is CEO and Dr. Jochen Schmitz is CFO; both were reappointed until February 28, 2031.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)